Actavia Life Sciences Inc RASP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.03
- Bid/Ask
- $0.01 / $0.02
- Market Cap
- $6.02 Mil
- Volume/Avg
- 15,000 / 2,656
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 1
- Website
- https://www.rasna.com
Valuation
|
Metric
|
RASP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RASP
Financial Strength
|
Metric
|
RASP
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | −20.31 |
Quick Ratio
RASP
Profitability
|
Metric
|
RASP
|
|---|---|
Return on Assets (Normalized) | −8,184.86% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RASP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rfjjdstnk | Tlbv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wgsxgdt | Zgjfgjp | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kyyczndm | Pxwkp | $98.9 Bil | |
MRNA
| Moderna Inc | Bgchgkvz | Vgsh | $39.7 Bil | |
ARGX
| argenx SE ADR | Bhfqbzn | Lsxv | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Wjpdmtyt | Qnwv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vfdbnmsfr | Pxlqqh | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rxjbzsp | Scskm | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kmkmcgdmr | Gpctmr | $12.3 Bil | |
INCY
| Incyte Corp | Sfmtpgfhb | Sbqmtz | $11.8 Bil |